Drug news
NICE in final guidance recommends Lixiana (edoxaban tosylate) to prevent stroke in patients with non valvular atrial fibrilliation- Daiichi Sankyo
The National Institute for Health and Care Excellence (NICE) has issued a final guidance recommending Lixiana (edoxaban tosylate) from Daiichi Sankyo to prevent stroke in patients withnon-valvular atrial fibrillation.
Comment: Lixiana, like other modern anticoagulants,Pradaxa (dabigatran), Xarelto (rivaroxaban) and Eliquis (apixaban> is seen as an alternative to warfarin and has a superior safety profile with less bleeding risk and less need for monitoring.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.